Former NFL quarterback Tom Brady and eMed CEO Linda Yaccarino announced a fixed-cost program to make GLP-1 weight-loss medications affordable for healthcare workers.
The initiative targets the rapidly rising cost of weight-loss drugs, attempting to expand access for medical professionals who are often priced out of these treatments. This move positions eMed as a direct player in a weight-loss drug market projected to exceed $100 billion [3].
Speaking at the Milken Institute Global Conference in Beverly Hills, California, Brady and Yaccarino discussed the growth of the Miami-based health-tech startup [1], [4]. Brady serves as a co-owner and the founding Chief Wellness Officer of the company [1].
The exclusive GLP-1 offer for healthcare workers launched on April 15, 2026 [4]. The program aims to mitigate the financial barriers associated with GLP-1 medications through a structured cost model [3].
Financial growth for the startup has been significant. eMed recently raised $200 million in funding [1], a move that brings the company's valuation to more than $2 billion [1].
Throughout the discussion, the leaders focused on the intersection of technology and wellness. They said there is a need for sustainable access to medication while exploring the broader business opportunities within the digital health sector [1], [3].
“eMed recently raised $200 million in funding”
The entry of high-profile figures like Tom Brady and Linda Yaccarino into the GLP-1 space signals a shift toward the 'democratization' of expensive weight-loss drugs through corporate health-tech platforms. By targeting healthcare workers specifically, eMed is leveraging a niche but influential demographic to scale its model in a market that is seeing explosive financial growth and high demand.
